Price
Financials
Standalone, Rs crore| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | 0.06 | -0.00 | 0.15 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.08 | 0.10 | 0.09 |
| Expenses | 0.06 | 0.02 | 0.23 | 0.14 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Operating Profit | -0.06 | 0.04 | -0.23 | 0.01 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | 0.06 | 0.07 | 0.05 |
| OPM % | 66.67% | 6.67% | 75.00% | 70.00% | 55.56% | |||||||
| Other Income | -0.00 | -0.00 | -0.00 | 0.01 | 0.05 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | -0.00 | -0.00 | -0.00 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 |
| Profit before tax | -0.08 | 0.02 | -0.25 | -0.00 | 0.02 | -0.03 | -0.03 | -0.07 | -0.05 | 0.04 | 0.05 | 0.03 |
| Tax % | -0.00% | 50.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -33.33% | |
| Net Profit | -0.08 | 0.01 | -0.25 | -0.00 | 0.02 | -0.03 | -0.03 | -0.06 | -0.05 | 0.05 | 0.05 | 0.04 |
| EPS in Rs | -2.07 | 0.26 | -6.46 | -0.00 | 0.52 | -0.78 | -0.78 | -1.55 | -1.29 | 1.29 | 1.29 | 1.03 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | -0.00 | -0.00 | -0.00 | 0.13 | -0.00 | 0.03 | 0.15 | 0.38 | -0.00 | 0.08 | 0.18 |
| Expenses | -0.00 | 0.07 | 0.05 | 0.09 | 0.16 | 0.34 | 0.08 | 0.36 | 0.41 | 0.06 | 0.04 | 0.06 |
| Operating Profit | -0.00 | -0.07 | -0.05 | -0.09 | -0.03 | -0.34 | -0.05 | -0.21 | -0.03 | -0.06 | 0.04 | 0.12 |
| OPM % | -23.08% | -1,950.00% | -166.67% | -140.00% | -7.89% | 50.00% | 66.67% | |||||
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.23 | 0.02 | 0.03 | 0.03 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.07 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.00 | -0.07 | -0.05 | -0.09 | -0.28 | -0.43 | -0.06 | -0.22 | -0.07 | -0.10 | -0.00 | 0.08 |
| Tax % | -0.00% | -0.00% | -0.00% | 3.57% | 2.33% | 16.67% | -0.00% | -0.00% | -0.00% | -0.00% | ||
| Net Profit | -0.00 | -0.07 | -0.05 | -0.09 | -0.30 | -0.43 | -0.06 | -0.22 | -0.07 | -0.09 | 0.01 | 0.08 |
| EPS in Rs | -0.00 | -17.77 | -12.38 | -22.28 | -74.26 | -11.12 | -1.55 | -5.69 | -1.81 | -2.33 | 0.26 | 2.07 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 43% | -22% | 125% | ||
| Compounded Profit Growth | 12% | 27% | 46% | 700% | ||
| Stock Price CAGR | % | -11% | -25% | -60% | ||
| Return on Equity | -21% | -11% | 0% | 16% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.04 | 0.04 | 0.04 | 0.04 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
| Reserves | 0.13 | 0.10 | 0.12 | 0.03 | -0.04 | 0.50 | 0.43 | 0.21 | 0.15 | 0.06 | 0.06 | 0.15 |
| Borrowings | 0.02 | 0.04 | 0.07 | 0.36 | 0.43 | 0.26 | 0.29 | 0.29 | 0.28 | 0.05 | 0.10 | 0.06 |
| Other Liabilities | -0.01 | 0.01 | -0.00 | 0.04 | 0.09 | 0.15 | 0.27 | 0.21 | 0.22 | 0.16 | 0.15 | 0.18 |
| Total Liabilities | 0.15 | 0.19 | 0.23 | 0.47 | 0.52 | 1.30 | 1.38 | 1.10 | 1.04 | 0.66 | 0.70 | 0.78 |
| Fixed Assets | 0.13 | 0.13 | 0.18 | 0.18 | 0.35 | 0.31 | 0.27 | 0.24 | 0.20 | 0.16 | 0.13 | 0.09 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 0.02 | 0.06 | 0.05 | 0.29 | 0.17 | 0.99 | 1.11 | 0.86 | 0.84 | 0.50 | 0.57 | 0.69 |
| Total Assets | 0.15 | 0.19 | 0.23 | 0.47 | 0.52 | 1.30 | 1.38 | 1.10 | 1.04 | 0.66 | 0.70 | 0.78 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.00 | -0.12 | -0.05 | -0.24 | 0.07 | -1.14 | 0.01 | -0.87 | -0.01 | 0.39 | -0.45 | 0.05 |
| Cash from Investing Activity | -0.00 | -0.00 | -0.05 | -0.00 | -0.19 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Cash from Financing Activity | -0.00 | 0.12 | 0.10 | 0.29 | 0.08 | 1.14 | 0.03 | -0.29 | -0.00 | -0.00 | 0.05 | -0.04 |
| Net Cash Flow | -0.00 | -0.00 | -0.00 | 0.05 | -0.05 | -0.00 | 0.04 | -1.16 | -0.01 | 0.39 | -0.40 | 0.01 |
| Free Cash Flow | -0.00 | -0.12 | -0.10 | -0.24 | -0.12 | -1.14 | 0.01 | -0.87 | -0.01 | 0.39 | -0.45 | 0.05 |
| CFO/OP | 171% | 100% | 267% | -233% | 335% | -20% | 414% | 33% | -650% | -1,125% | 42% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84.23 | -0.00 | -0.00 | -0.00 | 456.25 | 202.78 | ||||||
| Inventory Days | 328.50 | 13.04 | 19.21 | -0.00 | ||||||||
| Days Payable | 182.50 | 130.36 | 115.26 | |||||||||
| Cash Conversion Cycle | 230.23 | -0.00 | -117.32 | -96.05 | 456.25 | 202.78 | ||||||
| Working Capital Days | -280.77 | -2,676.67 | -924.67 | -384.21 | 2,007.50 | 1,034.17 | ||||||
| ROCE % | -0.00% | -41.18% | -24.39% | -27.27% | -11.63% | -45.57% | -5.31% | -22.00% | -8.19% | -15.15% | -0.00% | 13.91% |
| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 45.89% | 45.89% | 45.89% | 45.89% | 45.89% | 32.63% | 32.20% | 18.23% | 16.16% | 16.16% | 0.13% | 16.16% |
| Public | 54.11% | 54.11% | 54.11% | 54.11% | 54.10% | 67.36% | 67.81% | 81.76% | 83.84% | 83.84% | 99.87% | 83.84% |
| No. of Shareholders | 46 | 37 | 39 | 37 | 37 | 62 | 114 | 119 | 143 | 129 | 123 | 122 |
Fundamentals
Market Cap₹ 3.49 Cr.
Current Price₹ 90.3
Stock P/E43.6
Book Value₹ 14.0
ROCE13.9 %
ROE16.2 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)125%
Compounded Profit Growth (TTM)700%
Standalone figures.
Valuation
Market capRs 3 Cr
Enterprise valueRs 3 Cr
P/E (TTM)41.57x
Price to book6.16x
Price to sales18.48x
EV / EBITDA28.13x
EV / EBIT42.20x
EV / sales18.75x
Price to cash flow66.52x
Earnings yield2.41%
P/E, 3-year average425.09x
P/B, 3-year average21.78x
P/E, 5-year average425.09x
P/B, 5-year average16.34x
Profitability
Operating margin (excl. other income)66.67%
Operating margin (incl. other income)66.67%
EBITDA margin66.67%
Pre-tax margin44.44%
Net profit margin44.44%
ROE16.16%
ROCE13.91%
ROA10.81%
ROE, 3-year average0.07%
ROCE, 3-year average-0.62%
ROA, 3-year average0.56%
ROE, 5-year average-8.61%
ROCE, 5-year average-7.86%
ROA, 5-year average-4.52%
ROIC (approx.)13.56%
Growth
Sales growth (latest year)125.00%
Profit growth (latest year)700.00%
Sales CAGR, 3 years-22.05%
Sales CAGR, 5 years43.10%
Per share
EPS (TTM)Rs 2.07
EPS (latest year)Rs 2.07
EPS, 3-year averageRs 0.00
EPS, 5-year averageRs -1.50
Book value per shareRs 13.96
Sales per shareRs 4.65
Cash flow per shareRs 1.29
Free cash flow per shareRs 1.29
Efficiency
Asset turnover0.23x
Fixed asset turnover2.00x
Debtor days203 days
Debtors turnover1.80x
Creditor days115 days
Cash conversion cycle203 days
Working capital days1034 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 0 Cr
Net debtRs 0 Cr
Debt to equity0.11x
Net debt / EBITDA0.42x
Owners' fund to total sources69.23%
Debt to assets7.69%
Cash flow
Cash from Operating Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Sales to cash flow3.60x
Statement figures
Net sales (TTM)Rs 0 Cr
Net sales (latest year)Rs 0 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total expenditure (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 0 Cr
ReservesRs 0 Cr
Shareholders' fundsRs 1 Cr
Total assetsRs 1 Cr
Net blockRs 0 Cr
ReceivablesRs 0 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)0.04
Ownership
Promoter holding16.16% (-2.07 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 6.16 is at the 8th percentile (median 14.14).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 542765 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -9.5% | -2.8% | -6.7 pts |
| 1 month | -54.7% | -6.8% | -47.9 pts |
| 3 years | -37.1% | +14.2% | -51.3 pts |
| 5 years | -46.5% | +27.9% | -74.3 pts |
Red flags
F-score 6 of 7| explain | Weak cash conversion Cash from operations was -192153584101141088% of net profit over the last 3 years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹0 Cr.
Net profit ₹0 Cr +166.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Transpact Enterprises Ltd?
Transpact Enterprises Ltd (542765) has a market capitalisation of Rs 3.49 Cr. at the 2026-09-01 close.
What is the P/E ratio of Transpact Enterprises Ltd?
Transpact Enterprises Ltd trades at a P/E of 43.6 on trailing twelve-month profit, at the 2026-09-01 close.
What were Transpact Enterprises Ltd's latest quarterly results?
In the Mar 2026 quarter, Transpact Enterprises Ltd sales was Rs 0 Cr and net profit was Rs 0 Cr.